The BioMedWire Podcast

This release has been disseminated on behalf of Oncotelic Therapeutics, which may include a paid advertisement.

NetworkNewsWire Editorial Coverage: The global oncology market is rapidly shifting toward smarter drug-delivery systems that enhance efficacy, reduce toxicity and improve patient outcomes. Traditional oral or IV drugs often face poor bioavailability and limited tumor targeting — a major bottleneck in cancer treatment success. Recent breakthroughs in nanomedicine are making headlines, as the FDA and global regulatory bodies increasingly endorse nanocarrier-based delivery for complex drugs. This surge underscores a larger industry trend: the race to improve how drugs reach and act within the body. Oncotelic Therapeutics Inc.’s (OTCQB: OTLC) (profile) Deciparticle(TM) platform exemplifies this shift. It offers a novel approach to increase the bioavailability and therapeutic index of existing cancer drugs, potentially transforming underperforming compounds into next-generation therapies. The recent advancement of Sapu-003 into human trials signals real-world momentum behind this vision, showing how innovation in delivery science can unlock new value across multiple drug candidates. Oncotelic Therapeutics is focused on making its mark in the oncology treatment space, along with other innovative leaders such as IO Biotech Inc. (NASDAQ: IOBT), Novartis AG (NYSE: NVS), Bicara Therapeutics Inc. (NASDAQ: BCAX) and Pfizer Inc. (NYSE: PFE)

The Global Shift Toward Smarter Drug Delivery

The pharmaceutical industry is entering an inflection point driven by the recognition that highly potent cancer drugs are only as effective as their ability to reach tumors with sufficient concentration. Many promising oncology drugs fail not because the therapy lacks biological power, but because the body absorbs only a fraction of the intended dose. Conventional oral and IV therapies struggle with poor solubility, steep metabolism and imprecise biodistribution, forcing high doses and resulting in systemic toxicity. This is especially problematic in mTOR inhibitors, kinase inhibitors, and vascular-disrupting agents, where dose-limiting toxicity can halt development even when preclinical data were strong.

As a result, the industry is increasingly prioritizing drug-delivery innovation as much as drug discovery itself. Nanomedicine, the engineering of sub-200-nanometer drug carriers, is rapidly becoming the leading solution to address absorption inefficiencies and off-target toxicity. These platforms are designed not only to protect the drug from premature degradation but also control its release and guide it more precisely to tumor environments. Leading market research estimates that the global nanomedicine market could surpass $500 billion by 2032, driven by oncology-focused breakthroughs that materially improve drug absorption and targeting.

Within oncology, nanocarrier delivery has accelerated following regulatory validations such as FDA approvals of nanoparticle-formulated chemotherapies and RNA therapies. These new formulations are not simply incremental improvements; they can transform once-marginal drugs into category-changing assets. As precision medicine evolves from mutation-targeting to delivery-optimizing, companies that control best-in-class bioavailability engines are positioned to redefine the competitive landscape.

To view the full publication, visit https://ibn.fm/oNe26

For further information about Oncotelic Therapeutics Inc., visit the Oncotelic Therapeutics profile.

For more information, please visit www.NetworkNewsWire.com

Please view full terms of use and disclaimers on the NNW website applicable to all content provided by NNW, wherever published or re-published: http://www.nnw.fm/Disclaimer

This release has been disseminated on behalf of Oncotelic Therapeutics, which may include a paid advertisement.

NetworkNewsWire Editorial Coverage: The global oncology market is rapidly shifting toward smarter drug-delivery systems that enhance efficacy, reduce toxicity and improve patient outcomes. Traditional oral or IV drugs often face poor bioavailability and limited tumor targeting — a major bottleneck in cancer treatment success. Recent breakthroughs in nanomedicine are making headlines, as the FDA and global regulatory bodies increasingly endorse nanocarrier-based delivery for complex drugs. This surge underscores a larger industry trend: the race to improve how drugs reach and act within the body. Oncotelic Therapeutics Inc.’s (OTCQB: OTLC) (profile) Deciparticle(TM) platform exemplifies this shift. It offers a novel approach to increase the bioavailability and therapeutic index of existing cancer drugs, potentially transforming underperforming compounds into next-generation therapies. The recent advancement of Sapu-003 into human trials signals real-world momentum behind this vision, showing how innovation in delivery science can unlock new value across multiple drug candidates. Oncotelic Therapeutics is focused on making its mark in the oncology treatment space, along with other innovative leaders such as IO Biotech Inc. (NASDAQ: IOBT), Novartis AG (NYSE: NVS), Bicara Therapeutics Inc. (NASDAQ: BCAX) and Pfizer Inc. (NYSE: PFE)

The Global Shift Toward Smarter Drug Delivery

The pharmaceutical industry is entering an inflection point driven by the recognition that highly potent cancer drugs are only as effective as their ability to reach tumors with sufficient concentration. Many promising oncology drugs fail not because the therapy lacks biological power, but because the body absorbs only a fraction of the intended dose. Conventional oral and IV therapies struggle with poor solubility, steep metabolism and imprecise biodistribution, forcing high doses and resulting in systemic toxicity. This is especially problematic in mTOR inhibitors, kinase inhibitors, and vascular-disrupting agents, where dose-limiting toxicity can halt development even when preclinical data were strong.

As a result, the industry is increasingly prioritizing drug-delivery innovation as much as drug discovery itself. Nanomedicine, the engineering of sub-200-nanometer drug carriers, is rapidly becoming the leading solution to address absorption inefficiencies and off-target toxicity. These platforms are designed not only to protect the drug from premature degradation but also control its release and guide it more precisely to tumor environments. Leading market research estimates that the global nanomedicine market could surpass $500 billion by 2032, driven by oncology-focused breakthroughs that materially improve drug absorption and targeting.

Within oncology, nanocarrier delivery has accelerated following regulatory validations such as FDA approvals of nanoparticle-formulated chemotherapies and RNA therapies. These new formulations are not simply incremental improvements; they can transform once-marginal drugs into category-changing assets. As precision medicine evolves from mutation-targeting to delivery-optimizing, companies that control best-in-class bioavailability engines are positioned to redefine the competitive landscape.

To view the full publication, visit https://ibn.fm/oNe26

For further information about Oncotelic Therapeutics Inc., visit the Oncotelic Therapeutics profile.

For more information, please visit www.NetworkNewsWire.com

Please view full terms of use and disclaimers on the NNW website applicable to all content provided by NNW, wherever published or re-published: http://www.nnw.fm/Disclaimer

NetworkNewsWire Editorial Coverage: Artificial intelligence (“AI”) is making inroads into every corner of medical technology, perhaps none more urgently than imaging. In breast cancer detection, where early diagnosis can mean the difference between life and death, AI-enhanced modalities present a chance to leap beyond the limits of mammography, tomosynthesis, and MRI. Globally, breast cancer remains one of the most common cancers in women. According to the World Health Organization (“WHO”), more than 2.3 million women were diagnosed with breast cancer in 2022, and approximately 670,000 women died from the disease globally. In the United States, the American Cancer Society (“ACS”) projects that 316,950 new invasive breast cancer cases will be diagnosed among women this year. The urgent, life-saving need for earlier and more accurate detection creates a powerful opportunity for innovation in diagnostic imaging. Amid this global challenge, companies advancing breast cancer diagnostics are entering a high-impact field. Among them, Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (profile) stands out with its next-generation IzoView Breast CT Imaging System, a dedicated 3D imaging platform designed to improve detection accuracy, particularly for women with dense breast tissue. IzoView joins an elite group of companies, including Hologic Inc. (NASDAQ: HOLX), GE HealthCare Technologies Inc. (NASDAQ: GEHC), Nano-X Imaging Ltd. (NASDAQ: NNOX) and Oracle Corp. (NYSE: ORCL), that are focused on playing a transformative role in the use of AI in the medical imaging sector.

AI and 3D Imaging: The New Frontiers of Detection

The convergence of AI and three-dimensional (“3D”) medical imaging marks a turning point in diagnostic medicine. While traditional mammography has been a life-saving screening tool for decades, it is inherently constrained by its two-dimensional projection format and the physical compression required to visualize internal structures.

In dense breast tissue, present in more than one-half of women, lesions can be obscured or distorted, leading to reduced sensitivity and delayed detection. Research confirms that dense fibroglandular tissue can mask or mimic breast cancers, thereby lowering diagnostic accuracy and increasing the risk of missed cases, with one study reporting that mammography performance declines significantly in dense breasts, as overlapping tissue often conceals malignancies.

The emergence of AI-driven image reconstruction and analysis now offers a transformative solution to these long-standing challenges. Advanced algorithms can enhance contrast, reduce image noise and identify subtle patterns invisible to human interpretation. AI-based methods have also been shown to improve CT image quality while maintaining or reducing radiation dose, producing clearer and safer diagnostic results. In breast imaging specifically, recent reviews highlight that deep learning systems can augment or even match radiologist performance in lesion detection, segmentation and classification, particularly in dense tissue or early-stage disease.

This integration of AI with volumetric imaging technologies, such as tomosynthesis, MRI and dedicated breast CT, signals a broader shift toward intelligent diagnostics capable of generating and interpreting 3D data simultaneously. Radiology experts anticipate that AI will continue to revolutionize accuracy and efficiency across medical imaging, supporting clinicians in faster and more reliable decision-making.

Within this environment, Izotropic’s IzoView Breast CT Imaging System is designed to operate between digital breast tomosynthesis and MRI, combining high-resolution volumetric imaging with proprietary AI reconstruction technology. Its trade-secret algorithm, built on more than a decade of specialized breast CT data, and its potential integration with future computer-aided diagnosis (“CADx”) tools position IzoView squarely at the frontier of AI-empowered breast cancer detection.

To view the full publication, visit https://ibn.fm/33JVK

For further information about Izotropic Corporation, please visit the Izotropic Corporation profile.

For more information, please visit www.NetworkNewsWire.com

Please view full terms of use and disclaimers on the NNW website applicable to all content provided by NNW, wherever published or re-published: http://www.nnw.fm/Disclaimer

NetworkNewsWire Editorial Coverage: Artificial intelligence (“AI”) is making inroads into every corner of medical technology, perhaps none more urgently than imaging. In breast cancer detection, where early diagnosis can mean the difference between life and death, AI-enhanced modalities present a chance to leap beyond the limits of mammography, tomosynthesis, and MRI. Globally, breast cancer remains one of the most common cancers in women. According to the World Health Organization (“WHO”), more than 2.3 million women were diagnosed with breast cancer in 2022, and approximately 670,000 women died from the disease globally. In the United States, the American Cancer Society (“ACS”) projects that 316,950 new invasive breast cancer cases will be diagnosed among women this year. The urgent, life-saving need for earlier and more accurate detection creates a powerful opportunity for innovation in diagnostic imaging. Amid this global challenge, companies advancing breast cancer diagnostics are entering a high-impact field. Among them, Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (profile) stands out with its next-generation IzoView Breast CT Imaging System, a dedicated 3D imaging platform designed to improve detection accuracy, particularly for women with dense breast tissue. IzoView joins an elite group of companies, including Hologic Inc. (NASDAQ: HOLX), GE HealthCare Technologies Inc. (NASDAQ: GEHC), Nano-X Imaging Ltd. (NASDAQ: NNOX) and Oracle Corp. (NYSE: ORCL), that are focused on playing a transformative role in the use of AI in the medical imaging sector.

AI and 3D Imaging: The New Frontiers of Detection

The convergence of AI and three-dimensional (“3D”) medical imaging marks a turning point in diagnostic medicine. While traditional mammography has been a life-saving screening tool for decades, it is inherently constrained by its two-dimensional projection format and the physical compression required to visualize internal structures.

In dense breast tissue, present in more than one-half of women, lesions can be obscured or distorted, leading to reduced sensitivity and delayed detection. Research confirms that dense fibroglandular tissue can mask or mimic breast cancers, thereby lowering diagnostic accuracy and increasing the risk of missed cases, with one study reporting that mammography performance declines significantly in dense breasts, as overlapping tissue often conceals malignancies.

The emergence of AI-driven image reconstruction and analysis now offers a transformative solution to these long-standing challenges. Advanced algorithms can enhance contrast, reduce image noise and identify subtle patterns invisible to human interpretation. AI-based methods have also been shown to improve CT image quality while maintaining or reducing radiation dose, producing clearer and safer diagnostic results. In breast imaging specifically, recent reviews highlight that deep learning systems can augment or even match radiologist performance in lesion detection, segmentation and classification, particularly in dense tissue or early-stage disease.

This integration of AI with volumetric imaging technologies, such as tomosynthesis, MRI and dedicated breast CT, signals a broader shift toward intelligent diagnostics capable of generating and interpreting 3D data simultaneously. Radiology experts anticipate that AI will continue to revolutionize accuracy and efficiency across medical imaging, supporting clinicians in faster and more reliable decision-making.

Within this environment, Izotropic’s IzoView Breast CT Imaging System is designed to operate between digital breast tomosynthesis and MRI, combining high-resolution volumetric imaging with proprietary AI reconstruction technology. Its trade-secret algorithm, built on more than a decade of specialized breast CT data, and its potential integration with future computer-aided diagnosis (“CADx”) tools position IzoView squarely at the frontier of AI-empowered breast cancer detection.

To view the full publication, visit https://ibn.fm/33JVK

For further information about Izotropic Corporation, please visit the Izotropic Corporation profile.

For more information, please visit www.NetworkNewsWire.com

Please view full terms of use and disclaimers on the NNW website applicable to all content provided by NNW, wherever published or re-published: http://www.nnw.fm/Disclaimer

AUSTIN, Texas, October 22, 2025 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features the return of Dr. Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics Inc. (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing transformative oncology and immunotherapy treatments.

Dr. Trieu kicked off the conversation with a major update on Oncotelic’s latest clinical milestone: the advancement of Sapu-003, a novel IV formulation of everolimus (Afinitor®) built on Oncotelic’s proprietary Deciparticle™ platform.

“We’re very excited about the Sapu-003 approval to start a Phase 1 clinical trial,” he said. “This is a drug that targets breast cancer specifically… Breast cancer is roughly $30–40 billion in terms of addressable market size and [is forecast to] grow beyond that to roughly $50 billion by 2030. We feel that this drug candidate really has a lot of potential to change how breast cancer patients get treated and improve on Afinitor®, which is already a blockbuster drug.”

He then explained how the company’s Deciparticle™ nanomedicine platform addresses one of the biggest limitations of current mTOR inhibitors—poor bioavailability.

“If administered orally, only 10% of Afinitor® gets into the tissues, into the tumor. Bioavailability is low, so patients have to really take a lot of the drug to get enough in to kill the tumor, exposing themselves to gastric toxicity. With Sapu-003, we inject the drug directly, so 100% of the drug goes straight to the tumor… It kills off the tumor, and [there’s] a very minimal amount in the gut. You don’t have that gut toxicity that comes with oral administration.”

Looking ahead, Dr. Trieu outlined an aggressive development timeline for Sapu-003 and the broader Deciparticle™ pipeline.

“Our focus has always been to accelerate development as quickly as we can to get to market approval… This is an example where we took it from concept to clinical trial in less than one year… We anticipate finishing Phase 1 fairly quickly and then moving to Phase 3. So, within 2–3 years, we would like to have this drug product approved, which is faster than traditional drug development, where you’re looking at 10–15 years for approval.”

Join IBN’s Carmel Fisher for a follow-up conversation with Dr. Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics, as he shares how Sapu-003 and the Deciparticle™ platform are reshaping the company’s approach to oncology innovation and clinical execution.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 19 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Oncotelic Therapeutics

Oncotelic Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates.

In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued U.S. patents. Beyond its internal programs, the company also licenses and co-develops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Dr. Trieu’s leadership and guidance, which is advancing its own pipeline of drug candidates that further complement and strengthen Oncotelic’s strategic position in oncology and rare disease therapeutics.

For more information, visit the company’s website at www.Oncotelic.com

About IBN

IBN consists of financial brands introduced to the investment public over the course of 19+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN

AUSTIN, Texas, October 22, 2025 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features the return of Dr. Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics Inc. (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing transformative oncology and immunotherapy treatments.

Dr. Trieu kicked off the conversation with a major update on Oncotelic’s latest clinical milestone: the advancement of Sapu-003, a novel IV formulation of everolimus (Afinitor®) built on Oncotelic’s proprietary Deciparticle™ platform.

“We’re very excited about the Sapu-003 approval to start a Phase 1 clinical trial,” he said. “This is a drug that targets breast cancer specifically… Breast cancer is roughly $30–40 billion in terms of addressable market size and [is forecast to] grow beyond that to roughly $50 billion by 2030. We feel that this drug candidate really has a lot of potential to change how breast cancer patients get treated and improve on Afinitor®, which is already a blockbuster drug.”

He then explained how the company’s Deciparticle™ nanomedicine platform addresses one of the biggest limitations of current mTOR inhibitors—poor bioavailability.

“If administered orally, only 10% of Afinitor® gets into the tissues, into the tumor. Bioavailability is low, so patients have to really take a lot of the drug to get enough in to kill the tumor, exposing themselves to gastric toxicity. With Sapu-003, we inject the drug directly, so 100% of the drug goes straight to the tumor… It kills off the tumor, and [there’s] a very minimal amount in the gut. You don’t have that gut toxicity that comes with oral administration.”

Looking ahead, Dr. Trieu outlined an aggressive development timeline for Sapu-003 and the broader Deciparticle™ pipeline.

“Our focus has always been to accelerate development as quickly as we can to get to market approval… This is an example where we took it from concept to clinical trial in less than one year… We anticipate finishing Phase 1 fairly quickly and then moving to Phase 3. So, within 2–3 years, we would like to have this drug product approved, which is faster than traditional drug development, where you’re looking at 10–15 years for approval.”

Join IBN’s Carmel Fisher for a follow-up conversation with Dr. Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics, as he shares how Sapu-003 and the Deciparticle™ platform are reshaping the company’s approach to oncology innovation and clinical execution.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 19 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Oncotelic Therapeutics

Oncotelic Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates.

In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued U.S. patents. Beyond its internal programs, the company also licenses and co-develops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Dr. Trieu’s leadership and guidance, which is advancing its own pipeline of drug candidates that further complement and strengthen Oncotelic’s strategic position in oncology and rare disease therapeutics.

For more information, visit the company’s website at www.Oncotelic.com

About IBN

IBN consists of financial brands introduced to the investment public over the course of 19+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN

AUSTIN, Texas, September 22, 2025 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Dr. Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics Inc. (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing transformative oncology and immunotherapy treatments.

To begin the interview, Dr. Trieu provided an overview of the company’s mission and therapeutic scope.

“Oncotelic is a clinical-stage biotechnology company. We’re developing drugs to treat cancer and other rare diseases such as Parkinson’s and sexual dysfunction,” he said. “The team has been around for about 25 years. We originally developed Abraxane and, later, Cynviloq, and now we’re working on a lot of exciting drugs around oncology.”

He then discussed how Oncotelic’s development approach sets the company apart in the biotech space.

“What we have at Oncotelic is a really deep knowledge of the tumor microenvironment, as well as the regulatory pathway that we develop for each one of the drugs. When we take on an asset, we can easily build IP around it and protect it. Then, we push it out through a regulatory pathway that has the shortest timeline and highest chance of approval. That really differentiates us from everyone else.”

Looking ahead, Dr. Trieu outlined the key inflection points investors should watch.

“Our investors should be really looking forward to a lot of announcements from us in the next 12 months or so, both from the clinical side… as well as regulatory milestones such as IND approval, expansion into other indications, and partnership announcements… The team has been really focusing on operational execution—getting these drugs moving through clinical development, into trials, and toward approval.”

Join IBN’s Carmel Fisher for a conversation with Dr. Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics, to learn more about the company’s differentiated clinical pipeline and forward-looking development strategy.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 19 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Oncotelic Therapeutics

Oncotelic Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates.

In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 150 patent applications and holds 39 issued U.S. patents. Beyond its internal programs, the company also licenses and co-develops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Dr. Trieu’s leadership and guidance, which is advancing its own pipeline of drug candidates that further complement and strengthen Oncotelic’s strategic position in oncology and rare disease therapeutics.

For more information, visit the company’s website at www.Oncotelic.com

About IBN

IBN consists of financial brands introduced to the investment public over the course of 19+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN

AUSTIN, Texas, September 22, 2025 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Dr. Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics Inc. (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing transformative oncology and immunotherapy treatments.

To begin the interview, Dr. Trieu provided an overview of the company’s mission and therapeutic scope.

“Oncotelic is a clinical-stage biotechnology company. We’re developing drugs to treat cancer and other rare diseases such as Parkinson’s and sexual dysfunction,” he said. “The team has been around for about 25 years. We originally developed Abraxane and, later, Cynviloq, and now we’re working on a lot of exciting drugs around oncology.”

He then discussed how Oncotelic’s development approach sets the company apart in the biotech space.

“What we have at Oncotelic is a really deep knowledge of the tumor microenvironment, as well as the regulatory pathway that we develop for each one of the drugs. When we take on an asset, we can easily build IP around it and protect it. Then, we push it out through a regulatory pathway that has the shortest timeline and highest chance of approval. That really differentiates us from everyone else.”

Looking ahead, Dr. Trieu outlined the key inflection points investors should watch.

“Our investors should be really looking forward to a lot of announcements from us in the next 12 months or so, both from the clinical side… as well as regulatory milestones such as IND approval, expansion into other indications, and partnership announcements… The team has been really focusing on operational execution—getting these drugs moving through clinical development, into trials, and toward approval.”

Join IBN’s Carmel Fisher for a conversation with Dr. Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics, to learn more about the company’s differentiated clinical pipeline and forward-looking development strategy.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 19 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Oncotelic Therapeutics

Oncotelic Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates.

In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 150 patent applications and holds 39 issued U.S. patents. Beyond its internal programs, the company also licenses and co-develops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Dr. Trieu’s leadership and guidance, which is advancing its own pipeline of drug candidates that further complement and strengthen Oncotelic’s strategic position in oncology and rare disease therapeutics.

For more information, visit the company’s website at www.Oncotelic.com

About IBN

IBN consists of financial brands introduced to the investment public over the course of 19+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN

AUSTIN, Texas, September 19, 2025 – via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth,” featuring Oncotelic Therapeutics Inc. (OTCQB: OTLC).

To hear the NetworkNewsAudio version, visit LINK

To read the original editorial, visit LINK

At the helm of Oncotelic is Dr. Vuong Trieu, a biotech leader with a career defined by innovation and successful translation of science into practice. He has filed more than 500 patent applications and holds 75 issued patents — credentials that few industry executives can match. These patents cover a wide array of drug-development strategies, spanning oncology, immunotherapy and nanomedicine, reflecting his deep engagement in pioneering technologies.

Among Trieu’s most significant achievements has been his role in developing Abraxane(R), a nanotechnology-based formulation of paclitaxel bound to albumin nanoparticles. This innovation transformed the treatment landscape for breast, lung and pancreatic cancers and became a multibillion-dollar global therapy. Similarly, he advanced Cynviloq(TM), a novel micellar formulation of paclitaxel that improved delivery while reducing toxicities, further demonstrating his ability to reinvent cancer therapy.

About Oncotelic Therapeutics Inc.

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed more than 150 patent applications and holds 39 issued U.S. patents. Beyond its internal programs, the company also licenses and codevelops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Trieu’s leadership and guidance, which is advancing its own pipeline of drug candidates that further complement and strengthen Oncotelic’s strategic position in oncology and rare disease therapeutics.

For further information, please visit the company’s website at www.Oncotelic.com. 

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC

NetworkNewsAudio, a service of NetworkNewsWire (NNW), a multifaceted financial news and publishing company powered by IBN (“InvestorBrandNetwork”), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we're watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.

For more information, visit: www.NetworkNewsAudio.com

NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public. With an ever-growing distribution network of more than 5,000 key syndication outlets across the nation, NNW cuts through the overload of information in today's markets bringing its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire is where news, content and information converge.

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://NNW.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN

AUSTIN, Texas, September 19, 2025 – via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth,” featuring Oncotelic Therapeutics Inc. (OTCQB: OTLC).

To hear the NetworkNewsAudio version, visit LINK

To read the original editorial, visit LINK

At the helm of Oncotelic is Dr. Vuong Trieu, a biotech leader with a career defined by innovation and successful translation of science into practice. He has filed more than 500 patent applications and holds 75 issued patents — credentials that few industry executives can match. These patents cover a wide array of drug-development strategies, spanning oncology, immunotherapy and nanomedicine, reflecting his deep engagement in pioneering technologies.

Among Trieu’s most significant achievements has been his role in developing Abraxane(R), a nanotechnology-based formulation of paclitaxel bound to albumin nanoparticles. This innovation transformed the treatment landscape for breast, lung and pancreatic cancers and became a multibillion-dollar global therapy. Similarly, he advanced Cynviloq(TM), a novel micellar formulation of paclitaxel that improved delivery while reducing toxicities, further demonstrating his ability to reinvent cancer therapy.

About Oncotelic Therapeutics Inc.

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed more than 150 patent applications and holds 39 issued U.S. patents. Beyond its internal programs, the company also licenses and codevelops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Trieu’s leadership and guidance, which is advancing its own pipeline of drug candidates that further complement and strengthen Oncotelic’s strategic position in oncology and rare disease therapeutics.

For further information, please visit the company’s website at www.Oncotelic.com. 

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC

NetworkNewsAudio, a service of NetworkNewsWire (NNW), a multifaceted financial news and publishing company powered by IBN (“InvestorBrandNetwork”), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we're watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.

For more information, visit: www.NetworkNewsAudio.com

NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public. With an ever-growing distribution network of more than 5,000 key syndication outlets across the nation, NNW cuts through the overload of information in today's markets bringing its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire is where news, content and information converge.

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://NNW.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN